Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Common Equity (2016 - 2026)

Pharma-Bio Serv's Common Equity history spans 16 years, with the latest figure at $10.2 million for Q1 2026.

  • For Q1 2026, Common Equity fell 14.65% year-over-year to $10.2 million; the TTM value through Jan 2026 reached $10.2 million, down 14.65%, while the annual FY2025 figure was $11.9 million, 13.13% down from the prior year.
  • Common Equity reached $10.2 million in Q1 2026 per PBSV's latest filing, down from $11.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $17.4 million in Q1 2022 to a low of $10.2 million in Q1 2026.
  • Average Common Equity over 5 years is $14.4 million, with a median of $14.2 million recorded in 2024.
  • Peak YoY movement for Common Equity: crashed 32.26% in 2022, then grew 0.23% in 2023.
  • A 5-year view of Common Equity shows it stood at $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then fell by 14.95% to $13.7 million in 2024, then decreased by 13.13% to $11.9 million in 2025, then fell by 14.06% to $10.2 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Common Equity are $10.2 million (Q1 2026), $11.9 million (Q4 2025), and $11.9 million (Q3 2025).